Filing Flows › LifeStance Health Group (LFST) › Guidance & outlook
LifeStance Health Group (LFST) guidance and outlook
LifeStance Health Group (LFST) raised its guidance on Nov 5, 2026: Revenue $1.7B–$1.8B for FY2026; EBITDA $242M–$250M for FY2026; Revenue $446M–$466M for Q4 2026; EBITDA $56.0M–$64.0M for Q4 2026.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.7B–$1.8B | raised |
| EBITDA | FY2026 | $242M–$250M | raised |
| Revenue | Q4 2026 | $446M–$466M | new |
| EBITDA | Q4 2026 | $56.0M–$64.0M | new |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
LifeStance Health Group's latest quarter
LifeStance Health Group, Q3 2026: revenue $456M (+25% year over year), operating margin 7.3%, net earnings $22.4M, operating cash flow $37.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did LifeStance Health Group raise or lower its guidance?
LifeStance Health Group (LFST) raised its guidance on Nov 5, 2026: Revenue $1.7B–$1.8B for FY2026; EBITDA $242M–$250M for FY2026; Revenue $446M–$466M for Q4 2026; EBITDA $56.0M–$64.0M for Q4 2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.